Education
About Us
Working with TipRanks
Follow Us
Gh Research Plc (GHRS)
:GHRS
Top Page
GH Research
(NASDAQ:GHRS)
43Neutral
Positive Factors
Clinical Trial Success
GH Research announced positive top-line results from its Phase 2b trial evaluating GH001 in treatment-resistant depression, with significant improvement in depression symptoms and high remission rates.
Financial Stability
GHRS' cash balance, strengthened by a public offering, provides a financial runway into 2026, indicating financial stability.
Market Expansion
Positive efficacy signals in postpartum depression and bipolar depression highlight future expansion and potential upside.
Negative Factors
FDA Hold
A full response submission to remove the clinical hold on the US trial using the proprietary aerosol device is anticipated, which indicates a delay in trial progression until mid-2025.
Regulatory Challenges
Regulatory and commercial challenges are key investor concerns.
GH Research (GHRS) vs. S&P 500 (SPY)
Market Cap
$686.03M
Dividend YieldN/A
Average Volume (3M)270.43K
Price to Earnings (P/E)―
Beta (1Y)1.09
Revenue GrowthN/A
EPS Growth-9.46%
CountryUS
Employees50
SectorHealthcare
Sector Strength72
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.75
Shares Outstanding62,028,145
10 Day Avg. Volume183,245
30 Day Avg. Volume270,427
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$32.38Price Target Upside192.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
GH Research Business Overview & Revenue Model
Company DescriptionGH Research (GHRS) is a clinical-stage biopharmaceutical company focused on developing novel treatments for mental health disorders. The company operates primarily in the biotechnology and pharmaceutical sectors, with a core emphasis on researching and developing therapeutic solutions specifically targeting treatment-resistant depression and other mood disorders.
How the Company Makes MoneyGH Research makes money primarily through the development and eventual commercialization of its pharmaceutical products. Revenue streams are anticipated from the sale of proprietary medications following successful clinical trials and regulatory approval. Additionally, the company may engage in strategic partnerships or collaborations with larger pharmaceutical firms, potentially receiving milestone payments, royalties, or licensing fees. However, as a clinical-stage company, it currently relies on funding from investors, grants, and partnerships to support its research and development activities.
GH Research Financial Statement Overview
Summary
GH Research is in the early stages of revenue generation and faces significant challenges in terms of profitability and operational cash flow. The company has a strong equity base and low debt, which are positives. However, ongoing losses and negative cash flows are major concerns that need to be addressed to achieve long-term financial health.Income Statement
GH Research shows weak financial performance with consistently negative net income and EBIT. The gross profit margin is negative due to costs exceeding the revenue. However, the company has shown some revenue generation in the latest TTM, indicating potential for future growth.20
Very Negative
Balance Sheet
The balance sheet is relatively stable with a high equity ratio and low total debt, indicating strong financial stability. However, the company’s assets have been declining over time, and the return on equity is negative due to consistent losses.45
Neutral
Cash Flow
The cash flow statement indicates negative operating cash flow, reflecting ongoing operational challenges. Despite this, the company maintains a strong cash position, suggesting potential for future investment and growth.30
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 80.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | |||||
| -78.00K | -315.00K | -47.00K | -19.00K | 0.00 | 0.00 |
| EBIT | |||||
| -50.26M | -41.22M | -30.55M | -15.10M | -446.00K | -310.00K |
| EBITDA | |||||
| -38.27M | -41.15M | -30.63M | -15.08M | 0.00 | 0.00 |
| Net Income Common Stockholders | |||||
| -38.96M | -35.59M | -7.13M | -9.21M | -446.00K | -310.00K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 149.32M | 161.56M | 165.96M | 276.78M | 5.89M | 498.00K |
| Total Assets | |||||
| 188.27M | 226.30M | 254.36M | 279.92M | 5.91M | 504.00K |
| Total Debt | |||||
| 624.00K | 974.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt | |||||
| -100.17M | -77.45M | -165.96M | -276.78M | -5.89M | -498.00K |
| Total Liabilities | |||||
| 9.32M | 7.33M | 4.55M | 2.75M | 246.00K | 104.00K |
| Stockholders Equity | |||||
| 178.95M | 218.97M | 249.82M | 277.18M | 5.67M | 400.00K |
| Cash Flow | Free Cash Flow | ||||
| -42.33M | -33.44M | -26.27M | -15.39M | -1.11M | -289.00K |
| Operating Cash Flow | |||||
| -42.28M | -33.34M | -26.20M | -15.28M | -1.09M | -289.00K |
| Investing Cash Flow | |||||
| 65.14M | -54.10M | -84.69M | -104.00K | -21.00K | 0.00 |
| Financing Cash Flow | |||||
| -304.00K | -204.00K | 0.00 | 286.45M | 5.50M | 797.00K |
GH Research Technical Analysis
Negative
11.06
Price Trends
11.64
Negative
10.05
Positive
9.93
Positive
Market Momentum
0.16
Negative
45.98
Neutral
53.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GHRS, the sentiment is Negative. The current price of 11.06 is below the 20-day moving average (MA) of 11.19, below the 50-day MA of 11.64, and above the 200-day MA of 9.93, indicating a neutral trend. The MACD of 0.16 indicates Negative momentum. The RSI at 45.98 is Neutral, neither overbought nor oversold. The STOCH value of 53.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GHRS.
GH Research Risk Analysis
GH Research disclosed 1 risk factors in its most recent earnings report. GH Research reported the most risks in the “Legal & Regulatory” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GH Research Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
49 Neutral | $6.85B | 0.81 | -52.91% | 2.50% | 17.48% | 1.17% | |
43 Neutral | $201.54M | ― | -81.56% | ― | ― | 3.88% | |
43 Neutral | $686.03M | ― | -19.58% | ― | ― | -9.46% | |
42 Neutral | $9.85M | ― | -132.33% | ― | ― | 19.21% | |
42 Neutral | $1.97M | ― | -58.79% | ― | ― | 51.37% | |
42 Neutral | $291.51M | ― | -62.43% | ― | -0.90% | -89.51% | |
38 Underperform | $466.53M | ― | -68.01% | ― | ― | 26.24% |
* Healthcare Sector Average
Performance Comparison
GHRS
GH Research
11.06
-0.02
-0.18%
RLMD
Relmada Therapeutics
0.30
-4.58
-93.85%
TSE:CYBN
Cybin
0.14
0.00
0.00%
CMPS
COMPASS Pathways
2.94
-6.74
-69.63%
MNMD
Mind Medicine
6.19
-3.33
-34.98%
ATAI
ATAI Life Sciences
1.47
-0.39
-20.97%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.